Patient info Search Menu

Omvoh® 200 mg – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
Prescription only (POM) ▼ Additional monitoring
Medicine strength:
200 mg (100 mg/ml)
Contains active substance:

Patient leaflet - Omvoh 200 mg solution for injection in Pre-filled pen

1. What Omvoh is and what it is used for

Omvoh contains the active substance mirikizumab, a monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind specifically to certain target proteins in the body. Omvoh works by attaching to and blocking a protein in the body called IL-23 (interleukin-23), which is involved in inflammation. By blocking the action of IL-23, Omvoh reduces inflammation and other symptoms associated with ulcerative colitis.

Ulcerative colitis

Ulcerative colitis is a chronic inflammatory disease of the large bowel. If you have ulcerative colitis, you will first be given other medicines. If you do not respond well enough or cannot tolerate these medicines, you may be given Omvoh to reduce signs and symptoms of ulcerative colitis such as diarrhoea, abdominal pain, urgency and rectal bleeding.

2. What you need to know before you use Omvoh

Do not use Omvoh

  • if you are allergic to mirikizumab or any of the other

    ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice before using Omvoh.

  • If you have important active infections (active

    tuberculosis).

Warnings and precautions

  • Talk to your doctor or pharmacist before using this

    medicine.

  • Your doctor will check how well you are before treatment.
  • Make sure you tell your doctor about any illness you have

    before treatment.

Infections

  • Omvoh can potentially cause serious infections. Treatment

    with Omvoh should not be started if you have an active infection until the infection is gone.

  • After starting the treatment, tell your doctor right away if

    you have any symptoms of an infection such as:

    o fever o shortness of breath o chills o runny nose

    o muscle aches o sore throat

    o cough o pain during urination

  • Also tell your doctor if you have recently been near

    anyone who might have tuberculosis.

  • Your doctor will examine you and may do a test for

    tuberculosis before you have Omvoh.

  • If your doctor thinks you are at risk of an active

    tuberculosis, you may be given medicines to treat it.

Vaccinations

Your doctor will check to see if you need any vaccinations before starting treatment. Tell your doctor, pharmacist or nurse if you have recently had or are going to have a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Allergic reactions

  • Omvoh can potentially cause serious allergic reactions.
  • Stop using Omvoh and get emergency medical help right

    away if you develop any of the following symptoms of a serious allergic reaction:

    o rash o low blood pressure o fainting o swelling of the face, lips,

    mouth, tongue or throat, trouble breathing

    o dizziness o sensation of throat tightening

    or chest tightness.

Liver blood test

Your doctor will conduct blood tests before starting and during treatment with Omvoh to check if your liver is functioning normally. If blood tests are abnormal, your doctor might interrupt therapy with Omvoh and do additional tests on your liver to determine the cause.

Children and adolescents

Omvoh is not recommended for children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Omvoh

Tell your doctor, pharmacist or nurse

  • if you are using, have recently used or might use any

    other medicines.

  • if you have recently had or are going to have

    a vaccination. Some types of vaccines (live vaccines) should not be given while using Omvoh.

Pregnancy and breast‑feeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Omvoh in pregnancy. The effects of Omvoh in pregnant women are not known. If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and should use effective contraception while using Omvoh and for at least 10 weeks after the last Omvoh dose.

If you are breast-feeding or are planning to breast-feed, talk to your doctor before using this medicine.

Driving and using machines

Omvoh is unlikely to influence your ability to drive and use machines.

Omvoh contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium -free”.

Omvoh contains polysorbate

This medicine contains 0.3 mg/mL of polysorbate 80 in each pen which is equivalent to 0.6 mg for the maintenance dose to treat ulcerative colitis. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How to use Omvoh

Always use this medicine exactly as your doctor or nurse has told you. Check with your doctor, nurse or pharmacist if you are not sure how to use this medicine.

How much Omvoh is given and for how long

Your doctor will decide how much Omvoh you need and for how long. Omvoh is for long-term treatment. Your doctor or nurse will regularly monitor your condition to check that the treatment is having the desired effect.

Ulcerative colitis

  • Treatment start: The first dose of Omvoh is 300 mg and

    will be given by your doctor by intravenous infusion (drip in a vein in your arm) over at least 30 minutes. After the first dose, you will receive another dose of Omvoh 300 mg 4 weeks later and again after an additional 4 weeks. If you do not have adequate therapeutic response after these 3 infusions, your doctor might consider continuing intravenous infusions at weeks 12, 16 and 20.

  • Maintenance therapy: 4 weeks after the last intravenous

    infusion, a maintenance dose of Omvoh 200 mg will be given by an injection under the skin (‘subcutaneously’) and then every 4 weeks. The maintenance dose of 200 mg will be given by using 1 injection containing 200 mg of Omvoh.

    If you lose response after receiving the maintenance dose of Omvoh, your doctor may decide to give you 3 doses of Omvoh by intravenous infusions.

    Your doctor or nurse will tell you when to switch to subcutaneous injections.

    During maintenance therapy you and your doctor or nurse should decide if you should inject Omvoh yourself after training in subcutaneous injection technique. It is important not to try to inject yourself until you have been trained by your doctor or nurse. Your doctor or nurse will offer the necessary training.

    A caregiver may also give you your Omvoh injection after proper training.

    Use a reminder method such as notes in a calendar or diary to help you remember when to take your next dose so that you avoid missing or repeating doses.

If you receive more Omvoh than you should

If you have received more Omvoh than you should or the dose has been given sooner than prescribed, inform your doctor.

If you forget to use Omvoh

If you have forgotten to inject a dose of Omvoh, inject as soon as possible. Thereafter, resume dosing every 4 weeks.

If you stop using Omvoh

You should not stop using Omvoh without speaking to your doctor first. If you stop treatment, symptoms of ulcerative colitis may come back.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common (may affect more than 1 in 10 people)

  • Injection site reactions (e.g. red skin, pain)

Common (may affect up to 1 in 10 people):

  • Upper respiratory tract infections (nose and throat

    infections)

  • Joint pain
  • Headache
  • Rash

Uncommon (may affect up to 1 in 100 people): - Shingles

  • Infusion-related allergic reaction (e.g. itch, hives) - Increase in the level of liver enzymes in your blood.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Omvoh

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and on the outer carton after “EXP”. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C). Do not freeze.

Do not microwave the pen, run hot water over it, or leave it in direct sunlight.

Do not shake your pre-filled pen.

Store in the original packaging in order to protect from light. Omvoh may be stored unrefrigerated for up to 2 weeks at a temperature not above 30 °C.

If these conditions are exceeded, Omvoh must be discarded.

Do not use this medicine if you notice that the pre-filled pen is damaged, or the medicine is cloudy, distinctly brown, or has particles in it.

This medicine is for single use only.

Do not throw away any medicines via wastewater. Ask your doctor, nurse or pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Omvoh contains

  • The active substance is mirikizumab.

    Each pre-filled pen contains 200 mg of mirikizumab in 2 mL solution.

  • The other ingredients are histidine; histidine monohydrochloride; sodium chloride; mannitol (E 421); polysorbate 80 (E 433); water for injections.

What Omvoh looks like and contents of the pack

Omvoh is a solution in a clear glass cartridge encased in a disposable, single-use pen. Its colour may vary from colourless to slightly yellow.

Omvoh is available in packs containing 1 pre-filled pen of 200 mg and in multipacks comprising 3 cartons, each containing 1 pre-filled pen of 200 mg.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Eli Lilly Nederland B.V.

Orteliuslaan 1000,

3528 BD Utrecht,

The Netherlands

Manufacturer

Lilly France S.A.S.

Rue du Colonel Lilly

67640 Fegersheim

France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom

Eli Lilly and Company Limited

Tel: + 44-(0) 1256 315000

This leaflet was last revised in February 2026.

Note: Prints Head to Foot

NL149DAAA01

NL149DAAA01

Flip over to read INSTRUCTIONS FOR USE Q. What if I let my pens warm up for longer than 45 minutes before injecting? A. Your pen can stay at room temperature up to 30 °C for up to 2 weeks.

Q. What if I see air bubbles in the pen?

A. It is normal to have air bubbles in the pen. They will not harm you or affect your dose.

Q. What if there is a drop of liquid on the tip of the needle when I remove the grey base cap?

A. It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.

Q. What if I unlocked the pen and pressed the blue injection button down until the injection is complete?

A. Do not remove the grey base cap. Do not use the pen. Talk to your doctor or pharmacist to get a new one.

Q. Do I need to hold the blue injection button down until the injection is complete? A. You do not need to hold the blue injection button down, but it may help you keep the

pen steady and firm against your skin.

Q. What if the needle did not retract after my injection?

A. Do not touch the needle or replace the grey base cap. Store the pen in a safe place to avoid an accidental needlestick and contact your doctor, pharmacist or nurse.

Q. What if there is a drop of liquid or blood on my skin after my injection? A. This is normal. Press a cotton ball or gauze over the injection site. Do not rub the injection site.

Q. What if I heard more than 2 clicks during my injection – 2 loud clicks and a soft one. Did I get my complete injection?

A. Some patients may hear a soft click right before the second loud click. That is the normal operation of the pen. Do not remove the pen from your skin until you hear the second loud click.

Q. How can I tell if my injection is complete?

A. After you press the blue injection button, you will hear 2 loud clicks. The second

loud click tells you that your injection is complete. You will also see the grey plunger at the top of the clear base.

  • Your healthcare provider should show you how to prepare and inject Omvoh using the pen. Do not inject yourself or someone else until you have been shown how to inject Omvoh.
  • The pre‑filled pen contains 1 dose of Omvoh. The Omvoh pen is for one-time use only. Do not share or reuse your pen. You may give or get an infection.
  • Your healthcare provider may help you decide where on your body to inject your dose. You can also read the “Choose your injection site” section of these instructions to help you choose which area can work best for you.
  • If you have vision or hearing problems, do not use Omvoh pen without help from a caregiver.
  • Keep the Instructions for use and refer to them as needed.

    Instructions for use

    Instructions for use

    Omvoh® 200 mg solution for injection in pre-filled pen mirikizumab

Read this before you inject Omvoh. Follow all the step-by-step instructions.

Read the full package leaflet for Omvoh inside this box to learn more about your medicine.

Last revised in September 2025

Omvoh® 200 mg solution for

injection in pre-filled pen

mirikizumab

Commonly asked questions

Important information you need to know before injecting Omvoh:

FPO

200 mg 200 mg

PPD Information Box

Information: Black

286

368

375

485

(to be destroyed)

NL149DAAA00

2172

Cool Gray 10

Note: Prints Head to Foot

  • Put the used pen in a sharps disposal container right away after use. Do not throw the pen directly into your household waste.

Grey plunger

Needle

Grey base cap

Clear base Parts of the Omvoh pen

Before you use the Omvoh pens, read and carefully follow all the step-by-step instructions.

Throw away the used pens

Press and Hold for up to 15 Seconds

  • Press and hold the blue injection button. You

    will hear a loud click (injection started).

  • Keep holding the clear base firmly against

    your skin. You will hear a second loud click in about 15 seconds after the first one (injection completed).

  • You will know the injection is complete when

    the grey plunger is visible.

  • Remove the pen from your skin.
  • If you have bleeding at the injection site,

    press a cotton ball or gauze over the injection site.

  • Do not rub the injection site.

3

Place and Unlock

  • Place and hold the clear base flat and firmly

    against your skin.

    Keep the base on your skin and turn the lock

    ring to the unlock position.

2

Uncap the pen

Make sure the pen is locked.

Leave the grey base cap on until you are ready to inject.

  • Twist off the grey base cap and throw it away in your household waste.
  • Do not put the grey base cap back on – this could damage the needle.
  • Do not touch the needle.

Injecting Omvoh

Preparing to inject Omvoh

Choose your injection site

Your healthcare provider can help you choose the injection site that is best for you.

  • You or another person may inject the medicine into your stomach area (abdomen). Do not inject within 5 centimetres of the belly button (navel).
  • You or another person may inject the medicine in the front of your thighs. This area should be at least 5 centimetres above the knee and 5 centimetres below the groin.
  • Another person may give you the injection in the back of your upper arm.
  • Do not inject into areas where the skin is tender, bruised, red or hard.

Clean the injection site with an alcohol wipe. Let the injection site dry before you inject your medicine.

Wash your hands with soap and water before you inject Omvoh.

Prepare for injection

Supplies:

  • 1alcohol wipe
  • 1 cotton ball or piece of gauze
  • 1 sharps container (see “Disposing of Omvoh pens”) Gather supplies

Take the pen from the refrigerator

Open to read INSTRUCTIONS FOR USE Flip over for additional information Top

Lock ring

Blue injection button

Lock/unlock symbols

Bottom

Medicine

Needle

Clear base

Grey base cap

  • If you do not have a sharps disposal container, you may use a household container that is:

    • made of a heavy‑duty plastic,
    • can be closed with a tight fitting, puncture‑resistant lid, without sharps being able to come out,
    • upright and stable during use,
    • leak‑resistant,
    • properly labelled to warn of hazardous waste inside the container.
  • When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away needles and pens.
  • Do not recycle your used sharps disposal container.
  • For more information on how to dispose of the container properly, ask your healthcare provider about options available in your area.

Leave the grey base cap on until you are ready to inject.

Leave the pen at room temperature for 45 minutes before injecting.

Do not microwave the pen, run hot water over it, or leave it in direct sunlight.

Do not use the pen if the medicine is frozen. Do not shake.

15seconds Expiry date

Make sure you have the right medicine. The medicine inside should be clear. It may be colourless to slightly yellow.

Do not use the pen, and dispose of as directed by your healthcare provider if:

  • it looks damaged
  • the medicine is cloudy, is discoloured, or has particles
  • the expiry date printed on the label has passed
  • the medicine is frozen

Inspect the pen and the medicine

Disposing of Omvoh pens

FPO

You or another person may inject into these areas.

Another person should inject into this area.

PPD Information Box

Information: Black

286

368

375

485

(to be destroyed)

NL149DAAA00

2172

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 14895/0360

Last revision stated in the text: September 2025 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Omvoh 200 mg solution for injection in Pre-filled pen

What these facts mean

Prescription needed?? Yes, prescription-only medicine (POM)
Active substance? Mirikizumab
Strength? 200 mg (100 mg/ml)
Pharmaceutical form? Solution for injection
The solution is a clear and colourless to slightly yellow solution with a pH of approximately 5.5 and an osmolarity of approximately 300 mOsm/L.
How is it taken? Subcutaneous
Excipients? Histidine, Histidine monohydrochloride, Sodium chloride, Mannitol (E 421), Polysorbate 80 (E 433), Water for injections
Pack sizes 1 pre-filled disposable injection
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 2 years.
Storage Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Store in the original package in order to protect from light.
Omvoh may be stored unrefrigerated for up to 2 weeks at a temperature not above 30 °C.
If these conditions are exceeded, Omvoh must be discarded.
Drug group (ATC)? Immunosuppressants, interleukin inhibitors
Additional monitoring? Yes ▼ – it is being monitored particularly closely for safety. Report any side effect to the Yellow Card scheme.
Marketing authorisation? PL 14895/0360 (first authorised 27 February 2026)
Marketing authorisation holder? Eli Lilly Nederland B.V.
Codes? GTIN 5014602102128 · BNF 01050300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.